Patents by Inventor Vidal De La Cruz

Vidal De La Cruz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HMGB1 EXPRESSION AND PROTECTIVE ROLE OF SEMAPIMOD IN NEC
    Publication number: 20070282005
    Abstract: Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of iNOS protein, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of RAGE, or a combination thereof to a subject in need thereof.
    Type: Application
    Filed: June 1, 2006
    Publication date: December 6, 2007
    Inventors: Ruben Zamora, Henri Ford, Thais Sielecki-Dzurdz, Vidal de la Cruz
  • Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
    Publication number: 20050250826
    Abstract: The present invention provides a compound having Formula I or II: wherein B, R, X, Ar, and Y are defined herein, pharmaceutically acceptable salts thereof and pharmaceutically acceptable prodrugs thereof. The present invention also provides methods of making and using the compound.
    Type: Application
    Filed: March 28, 2005
    Publication date: November 10, 2005
    Inventors: Thais Sielecki-Dzurdz, Vidal De La Cruz
  • Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
    Publication number: 20050202010
    Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.
    Type: Application
    Filed: August 27, 2004
    Publication date: September 15, 2005
    Inventors: Brett Giroir, Monte Willis, Vidal De La Cruz, Thais Sielecki-Dzurdz
  • Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances
    Patent number: 5599912
    Abstract: The present invention provides methods of detecting and suppressing an undesired immune response, and agents suitable for use therein. More specifically, the present invention, provides agents and methods for their use, directed at detecting and suppressing an undesired immune response to compositions containing sulfamethoxazole.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: February 4, 1997
    Assignee: Coretech, Inc.
    Inventors: Timothy C. Rodell, Vidal De La Cruz, Catherine McCall, James K. Blodgett, Donald A. McLeod